

1 **Evaluation of a throat spray with lactobacilli in COVID-19 outpatients in a randomized, double-blind,**
2 **placebo-controlled trial for symptom and viral load reduction**

3 Ilke De Boeck¹, Eline Cauwenberghs¹, Irina Spacova¹, Thies Gehrman¹, Tom Eilers¹, Lize Delanghe¹,
4 Stijn Wittouck¹, Peter A. Bron¹, Tim Henkens², Imane Gamgami², Alix Simons², Ingmar Claes², Joachim
5 Mariën^{3,4}, Kevin K. Ariën^{3,5}, Diana Bakokimi³, Katherine Loens⁶, Kevin Jacobs⁶, Margareta Ieven⁶,
6 Patricia Bruijning-Verhagen⁷, Peter Delputte⁶, Samuel Coenen^{8,9}, Veronique Verhoeven⁸, Sarah
7 Lebeer¹⁵

8 ¹Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience Engineering, University of
9 Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium. ²YUN NV, Niel, Belgium. ³Virology Unit, Department of
10 Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. ⁴Evolutionary Ecology Group, Department of Biology,
11 University of Antwerp, Antwerp, Belgium. ⁵Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
12 ⁶Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Antwerp, B-2610, Belgium. ⁷Julius Centre for
13 Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, The
14 Netherlands, ⁸Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium. ⁹Vaccine &
15 Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

16 \$ corresponding author

17 **Abstract**

18 **Objectives:** Primary care urgently needs treatments for COVID-19 patients because current options
19 are limited, while these patients account for more than 90% of the people infected with SARS-CoV-2.

20 **Methods:** We evaluated a throat spray containing three *Lactobacillaceae* strains with broad antiviral
21 properties in a randomized double-blind placebo-controlled trial. Seventy-eight eligible COVID-19
22 patients were randomized to verum (n=41) and placebo (n=37) within 96 hours of positive PCR-based
23 SARS-CoV-2 diagnosis and per-protocol analysis was performed. Symptoms and severity were reported
24 daily via an online diary. Combined nose-throat swabs and dried blood spots were collected at regular
25 time points in the study.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Results:** The daily reported symptoms were highly variable, with no added benefit for symptom
27 resolution in the verum group. Specific monitoring of the applied lactobacilli strains showed that they
28 were detectable via microbiome (27%) and qPCR analysis (82%) of the verum group. Their relative
29 abundances were also negatively correlated with the acute symptom score. At the end of the trial, a
30 trend towards lower SARS-CoV-2 viral loads was observed for the verum group (2/30, 6.7% positive)
31 compared to the placebo group (7/27, 26% positive) ($p = 0.07$).

32 **Conclusions:** Despite a trend towards lower SARS-CoV-2 viral loads at the end of the trial and a negative
33 correlation between relative abundances of the applied lactobacilli in the microbiome and acute
34 symptoms, we did not observe a significant effect on overall symptom score for the verum group. This
35 suggests that studies with earlier application of the spray in larger study populations are needed to
36 further assess application potential.

37 **Introduction**

38 During the COVID-19 pandemic, most research and clinical trials on treatment options have been
39 conducted in hospitalized patients. This especially applies to intervention studies, which are routinely
40 executed in a hospital setting in critically ill patients. However, only 10-20% of COVID-19 patients need
41 medical care in hospitals [1]. While these numbers vary depending on the dominating SARS-CoV-2
42 variant, this means that the majority of COVID-patients have mild to moderate symptoms, are not
43 hospitalized, and depend only on treatments such as antiflogistics and analgesics [1,2]. Nevertheless,
44 these milder cases exert a significant burden on healthcare professionals in primary care [2,3]. In
45 addition, asymptomatic and presymptomatic transmission is the main driver for to others [4].
46 Respiratory viral infections can have severe health consequences due to imbalanced immune
47 activation and bacterial co-infections associated with airway tissue disruption and severe inflammation
48 [5]. This clearly shows the urge for more treatment and/or prevention options in COVID-19
49 outpatients, which can improve different aspects of the disease: symptom relieve, transmission
50 reduction and decreased hospitalization.

51 Microbiome or probiotic therapy is an emerging alternative treatment option for respiratory viral
52 diseases based on the potential multifactorial action of beneficial bacteria in the airways [6]. While
53 oral administration of such microbiome therapeutics or probiotics remains most common [7], this
54 route relies on systemic effects to ameliorate respiratory infections. Also during the current COVID-19
55 pandemic, oral administrations targeting the gut have already been explored [8–10]. Alternatively,
56 topical application of rationally-selected probiotics in the airways might offer several advantages [11],
57 as this could lead to direct blocking or inhibition of respiratory viruses [12], and direct immune
58 modulation at the site of infection and inflammation [13,14]. Indeed, the probiotic definition is not
59 limited to the gut [15]. We recently developed a microbiome-modulating throat spray with three
60 *Lactobacillaceae* strains that were selected based on their safety and *in vitro* multifactorial modes of
61 action on the key aspects of viral infection and disease, and their ability to thrive in the human
62 respiratory tract of healthy volunteers [16]. Yet, microbiome therapy with live bacteria has several
63 challenges, such as formulation and selection of target patient population.

64 Here, we evaluated the clinical potential of this throat spray with *Lacticaseibacillus casei* AMBR2,
65 *Lacticaseibacillus rhamnosus* GG, and *Lactiplantibacillus plantarum* WCFS1 against COVID-19 in a
66 randomized, double-blind, placebo-controlled trial in COVID-19 outpatients exhibiting mild-to-
67 moderate symptoms. Specifically, we monitored impact on symptom severity, time to improvement,
68 viral load, anti-SARS-CoV-2 antibodies and the respiratory microbiome in an out-of-hospital setting.
69 This trial relied on self-sampling and included collection of combined nose-throat swabs, fingerprick
70 blood samples and reporting of symptom and severity via an online diary.

71 **Methods**

72 **Clinical trial design:** A double-blind, placebo-controlled clinical trial was performed with a microbiome
73 throat spray in COVID-19 outpatients within 96 hours after a positive PCR test in government facilities
74 (see more details in supplementary methods). Approval was obtained from the committee of medical
75 Ethics (UZA/UAntwerpen, B3002021000018 and NCT04793997). Informed consent was obtained from

76 all participants prior to inclusion. Verum and placebo sprays were supplied by Yun NV (Niel, Belgium)
77 (supplementary methods). Randomization occurred in blocks of six patients with stratification for age
78 and gender and was done by the responsible clinicians (see supplementary methods for more details).

79 **Study procedures:** Patients were asked to use the verum spray or placebo for 14 days, with one week
80 of follow-up, and filled in an online diary via Qualtrics (Qualtrics, Provo, UT, USA) (detailed description
81 in Figure S1). Ten common COVID-19 symptoms were monitored, according to [17]. Different symptom
82 summary scores were compared between the verum and placebo groups, and time to improvement
83 was evaluated based on the timepoint when participants reached their symptomatic tipping point
84 (supplementary methods). Combined nose/throat swabs for microbiome analysis, determination of
85 SARS-CoV-2 viral loads and detection of administered *Lactobacillaceae* strains via qPCR and MiSeq
86 amplicon sequencing were self-sampled, as well as blood fingerprick samples (dried blood spots) to
87 analyze SARS-CoV-2 IgG antibodies (Figure S1 and supplementary methods).

88 **Outcomes:** The primary clinical outcome of this trial was the change in severity of COVID-19 infection
89 symptoms after using the microbiome spray. The secondary study outcomes included: (i) Change in
90 duration (time to improvement) of COVID-19 infection symptoms after using microbiome spray, (ii)
91 Change in absolute level of SARS-CoV-2 particles after using microbiome spray, (iii) Change in absolute
92 numbers of specific bacterial pathogens after using microbiome spray, and (iv) Change in microbiome
93 of nose/throat region after using microbiome spray.

94 Finally, some explorative (post-hoc) analyses were included: (i) relation of viral load with reported
95 symptoms, (ii) colonization of the administered strains in the airways and (iii) correlation of the
96 microbiome with several variables.

97 **Statistical analyses:** Per protocol analysis was performed on participants that completed the study and
98 provided samples on all timepoints. Standardized scores (z scores) were used for the analysis of the
99 primary outcome. The distributions of the severity score for four different symptom summary scores
100 (see supplementary methods) on every day between both treatment groups were compared. Kaplan

101 meier survival analysis was performed using the R survival package. The symptomatic tipping point
102 was taken as the event, and the time until occurrence was tested in the different treatment groups.
103 Differences between symptom scores in covid-positive and -negative participants (based on PCR) were
104 tested using a random effect model, $\text{symptom} \sim \text{covid} + (1|\text{participant})$. P-values were adjusted for
105 multiple testing using Bonferroni. Differential bacterial abundances between treatment groups were
106 tested with a random effect model with $\text{CLR}(\text{ra}) \sim \text{treatment} + \text{plate} + \text{qubit_score} + \text{library_size} +$
107 $(1|\text{participant})$, where CLR(ra) is the centered-log-ratio transformed relative abundance of a given
108 bacteria, and plate, qubit_score and library size constitute technical confounders. Effect sizes for the
109 treatment group were calculated for timepoints T2 and T3, at which the participants were using the
110 spray.

111 **Results**

112 **Set-up of a placebo-controlled intervention trial in mild-to-moderate COVID-19 patients and** 113 **assessment of study compliance and self-sampling**

114 The trial was conducted from February 24, 2021 to April 30, 2021 at the University of Antwerp.
115 Seventy-eight eligible patients were randomized, of which 41 were allocated to the verum spray and
116 37 to the placebo spray. Figure 1 depicts patient recruitment and enrollment. Fourteen participants
117 dropped out during the trial (7 verum, 7 placebo; reasons in Figure 1) and per protocol analysis of the
118 remaining participants that provided samples on all timepoints was conducted. Patient demographics,
119 reported symptoms at enrollment, and time between positive PCR test and start of intervention are
120 shown in Table 1.

121 The sprays were overall well-tolerated, but participants in both study groups often reported
122 unpleasant taste (mainly verum group) or texture (verum and placebo) of the spray. Also for the online
123 diaries, the compliance was high: the median number of completed diaries was 20/21 days, with 31.3%
124 of the study population showing full compliance, with filling in the diary every days. The compliance of

125 the self-sampling was 80.5% (509/632) for the combined nose/throat swabs, and 83.5% (132/158) for
126 the fingerprick blood samples.

127 **Monitoring of symptoms in primary- care patients and impact of the microbiome-throat spray on** 128 **symptom severity and time to improvement**

129 Symptoms at the start of the study are shown in Table 1. Cough (68%), runny/blocked nose (70%),
130 headache (65%) and fatigue (75%) were most frequently reported. The average total symptom score
131 at start of the study was 13.4 ± 8.6 in the verum group and 15.2 ± 9.3 in the placebo group (difference
132 not significant) (Table S1).

133 Severity of the symptoms was evaluated between both treatment groups over the study via the
134 distribution of the different severity scores (total, URT, acute and symptom) at every day (see also
135 Table S1). The same tendency for the verum and placebo group was observed with no significant
136 differences (Figure 2A-D). Independent of treatment, raw symptoms scores showed high inter- and
137 intra-individual fluctuation patterns (Figure S2), and scores were therefore propagated, smoothed
138 and standardized (Figure S3). Furthermore, time to improvement was not significantly different
139 between treatment groups and log odds (cox regression) were 0.125 ± 0.3 , -0.003 ± 0.3 , 0.111 ± 0.3 ,
140 0.58 ± 0.3 for total, system, URT and acute scores, respectively (Figure 2E-H). Over the entire study
141 population, 59% of the individuals (independent of treatment) still experienced symptoms after 21
142 days. At this three-week timepoint, 5% reported acute symptoms, 39% systemic symptoms and 41%
143 URT symptoms.

144 **Impact of the microbiome spray on SARS-CoV-2 viral loads and relation with symptoms**

145 At the start of the trial, 4/34 participants in the verum group and 3/30 participants in the placebo group
146 had a negative RT-qPCR result despite testing positive less than 96h earlier. After one week, 73% of
147 the participants in the verum group and 77% in placebo group tested positive ($p = 1$, Fisher's exact
148 test), while after 2 weeks this was 17% and 32%, respectively ($p = 0.22$, Fisher's exact test). At the end
149 of the trial, 2/30 (6.7%) patients in the verum group and 7/27 (26%) patients in the placebo group still

150 tested positive ($p = 0.07$, Fisher's exact test) (Figure 3A, 3B). Independent of the intervention, all
151 symptoms had a strong correlation with being SARS-CoV-2 positive (Table S2), although several
152 symptoms, such as cough, nasal symptoms and fatigue, were still reported upon a negative PCR result
153 (Figure 3C).

154 Analysis of self-collected fingerprick blood samples showed that at the start of the study, only 4/61
155 enrolled COVID-19 patients were positive or borderline positive for anti-SARS-CoV-2 IgG based on
156 antibody reactivity against the receptor-binding domain (RBD), nucleocapsid (NCP) and spike proteins
157 (S1S2) of SARS-CoV-2 [18] (Figure 3D). After 3 weeks, 51/61 patients were positive or borderline
158 positive for anti-SARS-CoV-2 IgG, without significant differences between placebo and verum groups
159 ($p = 0.71$, Chi-square test).

160 **Impact of SARS-CoV-2 infection on the upper airway microbiome**

161 Principal coordinates analysis (PCoA) showed no major shifts in the overall nose/throat microbial
162 composition for the time points nor for the microbiome treatment (Figure 4A). However, specific
163 effects on abundances of certain taxa were observed. When focusing on abundances of the amplicon
164 sequence variants (ASVs) of the *Lactobacillaceae* strains administered with the throat spray, significant
165 differences were observed between verum and placebo groups at different time points with mean
166 relative abundances for the *L. casei* ASV, *L. plantarum* ASV and *L. rhamnosus* ASV in the verum group
167 found to be 1.6%, 1.3% and 0.5%, respectively, over the entire study (Figure 4B, Table S3). In the
168 placebo group, these numbers were below 0.01% for all three ASVs (see also Table S3). Prevalences
169 (presence) based on MiSeq data were 38.6%, 28% and 13.4% for the *L. casei* ASV, *L. plantarum* ASV
170 and *L. rhamnosus* ASV, respectively, while this was 10.5%, 7% and 2% in the placebo group, pointing
171 at the fact that the related taxa to the applied lactobacilli are also endogenously present, but in low
172 numbers. Therefore, the presence of the specifically applied *Lactobacillaceae* strains was also
173 confirmed via qPCR with clear difference between verum (on average detected in 82% of the study
174 population) and placebo (on average 21%) and also between the estimated CFU/ml counts of the three

175 strains, in a range of 10^8 CFU/ml for *L. casei* AMBR2, 10^7 CFU/ml for *L. plantarum* WCFS1, and 10^6
176 CFU/ml for *L. rhamnosus* GG, in line with the concentrations in which they were added in the throat
177 spray (Figure 4C, Table S4).

178 Next, we correlated the relative abundances of a selection of ASVs belonging to important airway
179 genera (*Rothia*, *Dolosigranulum*, *Streptococcus*, *Staphylococcus*, *Haemophilus*, *Moraxella*, and
180 *Lactobacillus*) with treatment, severity scores and viral load across all timepoints and made a further
181 selection based on the ASVs that showed the highest effect sizes (Figure 4D). *Lactobacillus* ASV 1
182 (potentially *L. casei/paracasei/zeae*), *Lactobacillus* 2 (potentially *L.*
183 *fabifermentans/paraplantarum/pentosus/plantarum*), and *Lactobacillus* ASV 4 (potentially *L.*
184 *rhamnosus*) have a strong significant enrichment in the verum group, which was true across all
185 timepoints and more pronounced on treatment timepoints only (Figure 4D). In addition to the
186 deliberately added bacteria, other ASVs were positively correlated with the verum group, including
187 *Moraxella* ASV 4 (*M. lacunata*), *Rothia* ASV 14 (*R. amarae*) and several commensal *Streptococcus* ASVs
188 (among others *thermophilus*, *rubneri* and *sanguinis*). On the other hand, negative correlations with
189 treatment were observed with the strongest effect sizes for *Dolosigranulum* ASV 1 (*D. pigrum*),
190 *Streptococcus* ASV 7 (*S. gordonii*) and *Streptococcus* ASV 6 (*S. crispatus/oligofermentans/sinensis*).

191 Finally, positive and negative correlations between the symptom scores and specific taxa, with
192 moderate effect sizes were found (Figure 4D). Of interest, a significant negative correlation was found
193 for the ASVs corresponding to the applied lactobacilli and the acute symptom score, indicating that
194 application of these lactobacilli could result in less acute symptoms. *Dolosigranulum* ASV 1, another
195 lactic acid bacterium, had a negative correlation with the acute symptom score severity and even with
196 the total score. Conversely, *Haemophilus* ASV 3 (*H. aegyptius*) positively correlated with the different
197 symptom scores. Viral load did not have significant associations with specific taxa.

198 Discussion

199 We evaluated the use of a specifically formulated topical microbiome throat spray with three selected
200 members of the *Lactobacillaceae* in a placebo-controlled, remote self-sampling study in COVID-19
201 outpatients. Detailed microbiome and qPCR analysis showed a detection of the applied strains in the
202 verum group in on average 82% of the participants based on qPCR with estimated concentrations
203 between 10^6 - 10^8 CFU/ml. Analysis of the self-reported symptoms showed a patient-dependent disease
204 progression with high intra- and interindividual variations and no significant effects of the intervention
205 on the primary outcome in this rather small study population. However, a trend of faster decreasing
206 viral loads was observed in the verum group compared to placebo, with after three weeks 6.7% and
207 26% of participants remaining positive based on RT-qPCR testing, respectively ($p = 0.07$). This remains
208 to be substantiated in follow-up studies.

209 A first key finding of the study was the personal fluctuations of COVID symptoms, which we could
210 document quite detailed thanks to online questionnaires that were developed within the Rapid
211 European COVID-19 Emergency Response research (RECOVER) project [17]. Another study with daily
212 monitoring of symptoms for two weeks also recently reported that the natural course of COVID-19
213 disease is highly patient-dependent and variable [19]. This highly fluctuating disease pattern and
214 subjective self-evaluation of the symptom scores also complicates studies on treatments for COVID-19
215 symptoms. For instance, no effects of oral azithromycin in outpatients on the absence of self-reported
216 symptoms after 14 days as primary outcome were observed in a study with 263 patients [20]. This was
217 confirmed in the large open-label, multi-arm PRINCIPLE trial for the azithromycin group ($n = 2265$) [21].
218 On the other hand, inhaled budesonide showed positive effects in COVID-19 outpatients at risk aged
219 50-65 years ($n = 4700$) with a benefit in time to self-reported recovery of 2.9 days for patients in the
220 budesonide group compared to usual care group [22]. While probiotic trials in COVID-19 outpatients
221 are scarce compared to drug interventions, at least two recent studies reported symptom
222 improvement. After intranasal administration of *Lactococcus lactis* W136 ($n = 23$), the proportion of
223 patients with fatigue was lower in the verum group than placebo on day 7 ($p = 0.02$). In addition,
224 patients in the verum group had reduced loss of sense of smell on day 9 ($p = 0.03$) and reduced

225 shortness of breath on day 8 ($p = 0.02$) and day 12 ($p = 0.04$) compared to placebo [23]. However, it
226 should be noted that the authors did not report any correction for multiple testing in this study, which
227 is also not yet peer reviewed. In another larger trial ($n = 300$) with an oral probiotic mixture of *L.*
228 *plantarum* strains and *Pediococcus acidilactici* KABP021, patients in the verum group reported fewer
229 days of fever, cough, headache, body aches and shortness of breath [8].

230 Our results on the viral loads at day 21 are promising and in line with our previously reported *in vitro*
231 data, where we showed that the microbiome members that were selected for the throat spray show
232 clear antiviral effects against coronaviruses under controlled *in vitro* study set-ups [16]. In the trial with
233 the oral probiotic *L. plantarum* strains and *Pediococcus acidilactici* KABP021, a significantly larger
234 reduction in nasopharyngeal viral load was observed in the verum group at day 15 and day 30 ($p <$
235 0.001) [8]. Our data on viral loads should be further substantiated, because our study had several
236 limitations. In addition to the already discussed high biological variation of COVID-19 disease
237 progression and the rather small study population, we also experienced a suboptimal timepoint of
238 intervention. The start point appeared too late after disease onset. This has also been observed in
239 other trials with antivirals for respiratory infections [24,25]. For local applications of probiotics or
240 microbiome therapeutics [6] compared to oral applications such as [8], it is especially important that
241 the antiviral bacteria are provided early enough in the viral infection process, considering the more
242 local mode of action. Oral probiotics target the gut and systemic immunity to reduce symptoms in later
243 phases [26]. Here, we had to rely on the standard government PCR testing procedures in Belgium,
244 resulting in a delay between testing and inclusion. Most participants started within 2-5 days after their
245 first symptoms, when the viral loads were highest. A study design with a more preventive set-up might
246 be more suitable to evaluate a microbiome throat spray with a mode of action early in the viral
247 infection process. Moreover, we also observed that most patients still experienced symptoms at the
248 end of the monitoring (5% still reported acute symptoms, 39% systemic symptoms and 41% URT
249 symptoms), so that follow-up work with any potential therapeutic or nutritional interventions in
250 outpatients preferably extends the follow-up period for the patients to evaluate long COVID effects.

251 Our finding of reduced viral loads also suggests some to-be-validated potential to reduce transmission
252 to household members and other high-risk contacts. In a prospective cohort study conducted in the
253 Netherlands and Belgium, it was shown that secondary transmission within households occurred in
254 44.4% of the households, mostly very early after the index patient was positive [17]. Moreover, it might
255 be useful for future studies to stratify potential responders and non-responders based on the
256 microbiome (e.g. exclude patients with high relative abundances of lactic acid bacteria *Dolosigranulum*
257 because of the negative correlation found here with treatment), which is currently not standard in
258 clinical trials with microbiome therapeutics or probiotics. Moreover, an alternative formulation such
259 as a nose spray instead of the used throat spray, might be more favorable, since SARS-CoV-2 receptors
260 are highly expressed in nasal epithelium, and the alpha variant that was dominant during the study has
261 been shown to primarily target the nose [27]. In addition, based on in-house previous research, the
262 selected lactobacilli have several beneficial modes of action such as antimicrobial and
263 immunomodulatory properties, as well as barrier enhancing effects in the nasal epithelium [28–30].
264 However, this might also depend on the virus variant that is most dominant, because the current SARS-
265 CoV-2 Omicron (B.1.1.529) variant seems to target the throat as the first or main site with high viral
266 loads.

267 Since our study was one of the few in mild-to-moderate COVID patients outside the hospital and mostly
268 based on self-sampling, we also generated relevant information irrespective of the treatment
269 evaluated. In addition to the already mentioned intrapersonal fluctuations and interpersonal
270 variations of disease symptoms, we also observed a robust detection of SARS-CoV-2 virus in self-
271 collected combined nose/throat swabs. This exemplifies that a self-sampling approach for these types
272 of samples is feasible, in line with the previously demonstrated effectivity of SARS-CoV-2 detection in
273 oropharyngeal swabs collected by self-sampling during early infection to other read-outs and sample
274 types [31]. Furthermore, our results indicate robust detection of IgG against the SARS-CoV-2 RBD, NCP
275 and S1S2 antigens in self-collected dry blood spot samples, allowing detection of positive cases without
276 the need for blood collection by healthcare professionals. Remote study set-ups with self-sampling

277 and online questionnaires can thus represent a promising set-up for studies in COVID-19 outpatients
278 and other infectious diseases. Collecting samples without involvement of a third party could reduce
279 exposure, expand testing capacities, and minimize the burden on the hospitals and general
280 practitioners during the COVID-19 pandemic [31,32].

281 Taken together, our study suggests that the microbiome throat spray might have beneficial effects via
282 lowering nose/throat viral loads, potentially resulting in less virus transmission. Future studies are
283 required to investigate this transmission to for instance household members. We also believe that a
284 more preventive set-up is advised for the evaluation of this microbiome therapy, for instance for high-
285 risk contacts.

286 **Funding**

287 IDB and IS were supported by grants from Research Foundation - Flanders (FWO postdoctoral grants
288 12S4222N and 1277222N) and IDB also by a small research grant of the University of Antwerp (BOF KP
289 43829). EC is supported by the iBOF grant POSSIBL. TH, AS, and IC were supported by a research grant
290 from Flanders Innovation & Entrepreneurship (HBC.2020.2923). KKA was supported by the Research
291 Foundation - Flanders (G0G4220N) and by an intramural grant (a subsidy from the Department of
292 Economy, Science and Innovation (EWI) from the Flemish Government). LD was supported a Baekeland
293 mandate from Flanders Innovation & Entrepreneurship (HBC.2020.2873). SL, TH and TE were
294 supported by the European Research Council grant (Lacto-Be 26850). The application of the real-time
295 duplex PCR for the detection of SARS-CoV-2 and *RNAseP* was funded through the RECOVER project
296 (European Commission under H2020 call SC1-PHE-CORONAVIRUS-2020).

297 **Acknowledgements**

298 We would like to thank Sam Van Goethem for his advice on the study packages and logistics for the
299 home sampling. We also would like to thank all GPs that helped with the recruitment and all study
300 participants that participated in this trial. Furthermore, we want to thank the LebeerLab team, in
301 particular Ines Tuyaeerts, Nele Van de Vliet, Leen Van Ham, Marianne van den Broek, Sarah Ahannach,

302 Vincent Greffe, and Marie Legein. Finally, we would like to thank Biobank Antwerpen (Antwerp,
303 Belgium; ID: BE 71030031000).

304 **Conflict of interest statement**

305 IDB, IS, IC, TH and SL are inventors on a patent application (BE2021/5643) related to this work. IC, TH,
306 IG and AS are working at YUN NV (www.yun.be) who formulated the spray for this study. SL is a
307 member of the scientific advisory board of YUN NV. The PhD research of LD is currently funded by
308 VLAIO through a Baekeland mandate in collaboration with YUN NV. YUN was not involved in the clinical
309 study design or data analysis of this work. PAB is a consultant for multiple companies in the food and
310 health industry, but they were not involved in this manuscript. The remaining authors have no conflicts
311 of interest to declare related to this work.

312 **Data availability statement**

313 All data produced in the present study are available upon reasonable request to the authors or will be
314 deposited online after publication

315 **References**

- 316 [1] Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H, et al. Less severe
317 course of COVID-19 is associated with elevated levels of antibodies against seasonal human
318 coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1). *Int J Infect Dis* 2021;105:304–6.
319 <https://doi.org/10.1016/J.IJID.2021.02.085>.
- 320 [2] Verhoeven V, Tsakitzidis G, Philips H, Van Royen P. Impact of the COVID-19 pandemic on the
321 core functions of primary care: Will the cure be worse than the disease? A qualitative
322 interview study in Flemish GPs. *BMJ Open* 2020;10. [https://doi.org/10.1136/bmjopen-2020-](https://doi.org/10.1136/bmjopen-2020-039674)
323 [039674](https://doi.org/10.1136/bmjopen-2020-039674).
- 324 [3] Wanat M, Hoste M, Gobat N, Anastasaki M, Böhmer F, Chlabicz S, et al. Transformation of
325 primary care during the COVID-19 pandemic: experiences of healthcare professionals in eight

- 326 European countries. *Br J Gen Pract* 2021;71. <https://doi.org/10.3399/BJGP.2020.1112>.
- 327 [4] Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, et al. Effective control of SARS-CoV-2 transmission
328 in Wanzhou, China. *Nat Med* 2020 271 2020;27:86–93. [https://doi.org/10.1038/s41591-020-](https://doi.org/10.1038/s41591-020-01178-5)
329 01178-5.
- 330 [5] Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host
331 Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 2020;181:1036-1045.e9.
332 <https://doi.org/10.1016/J.CELL.2020.04.026>.
- 333 [6] Spacova I, De Boeck I, Bron PA, Delputte P, Lebeer S. Topical Microbial Therapeutics against
334 Respiratory Viral Infections. *Trends Mol Med* 2021;27:538–53.
335 <https://doi.org/10.1016/J.MOLMED.2021.03.009>.
- 336 [7] Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections.
337 *Cochrane Database Syst Rev* 2015. <https://doi.org/10.1002/14651858.CD006895.pub3>.
- 338 [8] Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, Nieto-Rufino CD, López-Orduña E,
339 Jiménez-Escobar I, et al. Probiotic improves symptomatic and viral clearance in Covid19
340 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. *Gut Microbes*
341 2022;14.
342 https://doi.org/10.1080/19490976.2021.2018899/SUPPL_FILE/KGMI_A_2018899_SM2404.D
343 OCX.
- 344 [9] Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti G Pietro, Cavallari EN, et al. Oral
345 Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. *Front Nutr* 2021.
346 <https://doi.org/10.3389/fnut.2020.613928>.
- 347 [10] d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al.
348 Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as
349 Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. *Front Med*

- 350 2020;7:389. <https://doi.org/10.3389/fmed.2020.00389>.
- 351 [11] De Boeck I, Spacova I, Vanderveken OM, Lebeer S. Lactic acid bacteria as probiotics for the
352 nose? *Microb Biotechnol* 2021;14:859–69. <https://doi.org/10.1111/1751-7915.13759>.
- 353 [12] Chen H-W, Liu P-F, Liu Y-T, Kuo S, Zhang X-Q, Schooley RT, et al. Nasal commensal
354 *Staphylococcus epidermidis* counteracts influenza virus. *Sci Rep* 2016;6:27870.
355 <https://doi.org/10.1038/srep27870>.
- 356 [13] Spacova I, Petrova MI, Fremau A, Pollaris L, Vanoirbeek J, Ceuppens JL, et al. Intranasal
357 administration of probiotic *Lactobacillus rhamnosus* GG prevents birch pollen-induced allergic
358 asthma in a murine model. *Allergy* 2019;74:100–10. <https://doi.org/10.1111/all.13502>.
- 359 [14] Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY, et al. Intranasal administration of live
360 *Lactobacillus* species facilitates protection against influenza virus infection in mice. *Antiviral*
361 *Res* 2012;93:138–43. <https://doi.org/10.1016/j.antiviral.2011.11.004>.
- 362 [15] Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific
363 Association for Probiotics and Prebiotics consensus statement on the scope and appropriate
364 use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014;11:506–14.
365 <https://doi.org/10.1038/nrgastro.2014.66>.
- 366 [16] Spacova I, De Boeck I, Cauwenberghs E, Delanghe L, Bron PA, Henkens T, et al. Live
367 biotherapeutic throat spray for respiratory virus inhibition and interferon pathway induction.
368 *BioRxiv* 2022:2022.01.25.477549. <https://doi.org/10.1101/2022.01.25.477549>.
- 369 [17] Verberk J, de Hoog M, Westerhof I, van Goethem S, Lammens C, Ieven M, et al. Transmission
370 of SARS-CoV-2 within households: A prospective cohort study in the Netherlands and Belgium
371 - Interim results. *MedRxiv* 2021:1–18. <https://doi.org/10.1101/2021.04.23.21255846>.
- 372 [18] Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating SARS-
373 CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild

- 374 COVID-19 cases using a Luminex bead-based assay. *J Virol Methods* 2021;288:114025.
375 <https://doi.org/10.1016/J.JVIROMET.2020.114025>.
- 376 [19] Rodebaugh TL, Frumkin MR, Reiersen AM, Lenze EJ, Avidan MS, Miller JP, et al. Acute
377 Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and
378 Over Time. *Open Forum Infect Dis* 2021;8. <https://doi.org/10.1093/OFID/OFAB090>.
- 379 [20] Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al. Effect of Oral
380 Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients with SARS-CoV-2 Infection: A
381 Randomized Clinical Trial. *JAMA - J Am Med Assoc* 2021;326:490–8.
382 <https://doi.org/10.1001/jama.2021.11517>.
- 383 [21] Butler CC, Dorward J, Yu LM, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for
384 community treatment of suspected COVID-19 in people at increased risk of an adverse clinical
385 course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
386 *Lancet* 2021;397:1063–74. [https://doi.org/10.1016/S0140-6736\(21\)00461-](https://doi.org/10.1016/S0140-6736(21)00461-X/ATTACHMENT/22EF69BB-C37F-48F3-BD10-92D88E328CCF/MMC1.PDF)
387 [X/ATTACHMENT/22EF69BB-C37F-48F3-BD10-92D88E328CCF/MMC1.PDF](https://doi.org/10.1016/S0140-6736(21)00461-X/ATTACHMENT/22EF69BB-C37F-48F3-BD10-92D88E328CCF/MMC1.PDF).
- 388 [22] Yu LM, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide
389 for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a
390 randomised, controlled, open-label, adaptive platform trial. *Lancet* 2021.
391 [https://doi.org/10.1016/S0140-6736\(21\)01744-X](https://doi.org/10.1016/S0140-6736(21)01744-X).
- 392 [23] Endam LM, Tremblay C, Filali A, Desrosiers MY. INTRANASAL APPLICATION OF LACTOCOCCUS
393 LACTIS W 136 BACTERIA EARLY IN SARS-Cov-2 INFECTION MAY HAVE A BENEFICIAL
394 IMMUNOMODULATORY EFFECT: A PROOF-OF-CONCEPT STUDY. *MedRxiv* 2021.
- 395 [24] Ison MG, Hayden FG. Antiviral Agents Against Respiratory Viruses. *Infect Dis (Auckl)*
396 2017;1318. <https://doi.org/10.1016/B978-0-7020-6285-8.00154-4>.
- 397 [25] Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P,

- 398 et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun 2017.
399 <https://doi.org/10.1038/s41467-017-00170-x>.
- 400 [26] Kanauchi O, Andoh A, AbuBakar S, Yamamoto N. Probiotics and Paraprobiotics in Viral
401 Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems. Curr
402 Pharm Des 2018. <https://doi.org/10.2174/1381612824666180116163411>.
- 403 [27] Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry
404 factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat
405 Med 2020. <https://doi.org/10.1038/s41591-020-0868-6>.
- 406 [28] De Boeck I, van den Broek MFL, Allonsius CN, Spacova I, Wittouck S, Martens K, et al.
407 Lactobacilli Have a Niche in the Human Nose. Cell Rep 2020;31:107674.
408 <https://doi.org/10.1016/J.CELREP.2020.107674>.
- 409 [29] Martens K, Boeck I De, Jokicevic K, Kiekens F, Farré R, Vanderveken OM, et al.
410 Lactocaseibacillus casei AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis
411 With Nasal Polyps. Allergy, Asthma, Immunol Res 2021;13.
- 412 [30] De Rudder C, Garcia-Tímermans C, De Boeck I, Lebeer S, Van de Wiele T, Calatayud Arroyo M.
413 Lactocaseibacillus casei AMBR2 modulates the epithelial barrier function and immune
414 response in a donor-derived nasal microbiota manner. Sci Rep 2020;10:1–16.
415 <https://doi.org/10.1038/s41598-020-73857-9>.
- 416 [31] Würstle S, Spinner CD, Voit F, Hoffmann D, Hering S, Weidlich S, et al. Self-sampling versus
417 health care professional-guided swab collection for SARS-CoV-2 testing. Infect 2021 2021;1:1–
418 8. <https://doi.org/10.1007/S15010-021-01614-9>.
- 419 [32] Majam M, Msolomba V, Scott L, Stevens W, Marange F, Kahamba T, et al. Self-Sampling for
420 SARS-CoV-2 Diagnostic Testing by Using Nasal and Saliva Specimens: Protocol for Usability and
421 Clinical Evaluation. JMIR Res Protoc 2021;10. <https://doi.org/10.2196/24811>.


422

423

424 **Table 1: Patient demographics and baseline characteristics by treatment group.** Due to missing values of 4
425 participants that did not complete or fill in the intake survey, this table is based on data from 60 participants.


	Verum (n = 33)	Placebo (n = 27)
Age (years) [mean, stdv]	42 ± 12	43 ± 12
Sex (female) [n, %]	21 [62%]	19 [63%]
Body Mass Index (BMI, kg/m²) [mean, stdv]	26.6 ± 4.8	26.1 ± 5.5
• Of which obesity (BMI >30)	4 [12%]	5 [19%]
Smoker (yes) [n, %]	4 [12%]	5 [19%]
Employment in		
• Patient care [n, %]	1 [3%]	1 [4%]
• Children care [n, %]	2 [6%]	1 [4%]
• Teaching [n, %]	7 [21%]	5 [19%]
Inhalation allergy [n, %]	15 [45%]	7 [26%]
Lung disease (asthma, COPD)	3 [9%]	4 [15%]
Cardiac disease (yes) [n, %]	2 [6%]	0 [0%]
Immune disorder (yes) [n, %]	1 [3%]	1 [4%]
Diabetes (yes) [n, %]	1 [3%]	1 [4%]
Hypertension [n, %]	3 [9%]	4 [15%]
Days from positive PCR test [median, range]	1 [-1,3]	1 [0-4]
Days since onset of symptoms [median, range]	3 [1-18]	2 [1-11]
Fever (yes) [n, %]	5 [15%]	7 [26%]
Cough (yes) [n, %]	24 [73%]	17 [63%]
Sore throat (yes) [n, %]	13 [39%]	9 [33%]
Runny/blocked nose (yes) [n, %]	20 [61%]	22 [81%]
Shortness of breath (yes) [n, %]	7 [21%]	7 [26%]
Headache (yes) [n, %]	21 [64%]	18 [67%]
Loss of smell and taste (yes) [n, %]	8 [24%]	5 [19%]
Muscle pain (yes) [n, %]	17 [52%]	15 [56%]
Chills (yes) [n, %]	13 [39%]	7 [26%]
Fatigue (yes) [n, %]	25 [76%]	20 [74%]
Diarrhea (yes) [n, %]	2 [6%]	2 [7%]

426




427

428 **Figure 1: CONSORT flowchart for patient recruitment and enrollment.** * Excluded for not meeting the inclusion
 429 criteria (mostly because time from positive PCR test was > 96 hours, often when people contacted the study
 430 coordinator in response to the press release message) or declined to participate after first contact with study
 431 coordinator. Of note, for the analysis of SARS-CoV-2 viral loads with RT-qPCR, 4 participants in the verum group
 432 and 3 participants in placebo already had a negative PCR test at T1 of our study. Hence, for this analysis, 30
 433 participants and 27 participants were analyzed for verum and placebo, respectively.



434


435 **Figure 2: Symptom severity and time to improvement.** Severity of the reported symptoms (A-D) was evaluated
436 based on different scoring systems: Total score (A), URT score (B), system score (C) and acute score (D). Results
437 are shown as standardized scores (z-score) to adjust for the highly subjective self-evaluation. Time to
438 improvement (E-H) was also evaluated for the 4 scoring systems between both study groups. Survival analysis
439 showed no significant differences for all tested scores between placebo and verum ($p > 0.1$).



440

441 **Figure 3: Viral loads in combined nose/throat swabs.** A) SARS-CoV-2 viral loads in combined nose-throat swabs
 442 determined via PCR at start (T1), after 1 week (T2), after 2 weeks (T3) and after 3 weeks/end of the study (T4).
 443 Results are shown as Ct values. B) Heatmap showing presence or absence of SARS-CoV-2 based on positive PCR
 444 test. Each vertical line represents one participant. C) Relation between self-reported symptoms and SARS-CoV-
 445 2 viral load. D) Presence of anti-SARS-CoV-2 IgG antibodies in the blood of COVID-19 patients (COV) at the start
 446 (T1) and at the end (T4) of study comprising 3 weeks in between. Data for treatment groups verum and placebo
 447 is depicted as number of participants positive, borderline or negative for anti-SARS-CoV-2 IgG as part of the total
 448 number of participants per treatment group per time point. Only participants with blood samples available at
 449 both T1 and T4 were included in this analysis.

450



451

452 **Figure 4: Microbial community composition in the airways (A), detection of the administered *Lactobacillaceae***

453 **strains (B-C) and correlation of treatment and symptom scores with bacterial taxa (D).** A) PCoA was used to

454 visualize the microbiome composition in combined nose/throat swabs for each treatment group and at the

455 different timepoints. T1 = start, T2 = after 1 week, T3 = after 2 weeks, and T4 = end trial. B) Relative abundances

456 of *L. casei* ASV, *L. plantarum* ASV and *L. rhamnosus* ASV between placebo and verum. See also Table S2 for mean

457 relative abundances for all ASVs at the different timepoints and statistics. C) qPCR with species-specific primers

458 for *L. rhamnosus* GG, *L. casei* AMBR2 and *L. plantarum* WCFS1 was used to estimate the CFU/ml counts. Based

459 on the standard curve, the detection limit was estimated to be at 10^3 CFU/ml. D) Correlation of treatment and

460 symptom scores with bacterial taxa across all timepoints in the study. For the treatment, the correlation was also

461 evaluated for treatment time only.

462